Therabron Therapeutics Overview
Latest Deal Type
Conv. Debt
Latest Deal Amount
$2.33M
Therabron Therapeutics General Information
Description
Developer of novel drugs with therapeutic proteins designed to cure respiratory diseases. The company's novel drugs with therapeutic proteins develop a series of recombinant human secretoglobins, enabling patients to access treatments for a range of orphan and more commonplace respiratory diseases impacting people from infancy through adulthood.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Therabron Therapeutics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 5. Convertible Debt |
27-Dec-2016 |
$2.33M |
00.000 |
|
Completed |
Clinical Trials - Phase 2 |
| 4. Later Stage VC (Series B) |
18-Nov-2015 |
00.00 |
00.000 |
000.00 |
Completed |
Generating Revenue |
| 3. Grant |
24-Sep-2012 |
00000 |
00000 |
|
Completed |
Startup |
| 2. Angel (individual) |
17-Sep-2012 |
$250K |
$565K |
|
Completed |
Startup |
| 1. Angel (individual) |
10-Nov-2011 |
$315K |
$315K |
|
Completed |
Startup |
Therabron Therapeutics Cap Table
To view Therabron Therapeutics‘s complete cap table, request access >>
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion Price |
% Owned |
| Series B |
000,000 |
00.000000 |
|
000.00 |
000.00 |
00 |
000.00 |
00.000 |
| Series A4 |
0,000 |
00.000000 |
|
000 |
000 |
00 |
000 |
0.000 |
| Series A3 |
00,000 |
00.000000 |
|
00 |
00 |
00 |
00 |
0.000 |
| Series A2 |
89,683 |
$0.001000 |
|
$6.3 |
$6.3 |
1x |
$6.3 |
2.2% |
| Series A1 |
116,279 |
$0.001000 |
|
$2.15 |
$2.15 |
1x |
$2.15 |
2.85% |
Therabron Therapeutics Executive Team (6)
| Name |
Title |
Board Seat |
Contact Info |
| Aprile Pilon Ph.D |
Founder, Chief Scientific Officer, Executive Vice President & Board Member |
|
|
5 Former Executives